These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34725190)

  • 1. Association of Homologous Recombination-DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers.
    Cerniglia M; Xiu J; Grothey A; Pishvaian MJ; Baca Y; Hwang JJ; Marshall JL; VanderWalde AM; Shields AF; Lenz HJ; Korn WM; Salem M; Philip PA; Goldberg RM; Zeng J; Kim SS
    Mol Cancer Ther; 2022 Jan; 21(1):227-236. PubMed ID: 34725190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma.
    Salem ME; Puccini A; Xiu J; Raghavan D; Lenz HJ; Korn WM; Shields AF; Philip PA; Marshall JL; Goldberg RM
    Oncologist; 2018 Nov; 23(11):1319-1327. PubMed ID: 29866946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing.
    Wang HY; Deng L; Li YQ; Zhang X; Long YK; Zhang X; Feng YF; He Y; Tang T; Yang XH; Wang F
    Cancer Res Treat; 2021 Oct; 53(4):973-982. PubMed ID: 33677848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy.
    Zhou KI; Peterson B; Serritella A; Thomas J; Reizine N; Moya S; Tan C; Wang Y; Catenacci DVT
    Clin Cancer Res; 2020 Dec; 26(24):6453-6463. PubMed ID: 32820017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.
    Ricciuti B; Recondo G; Spurr LF; Li YY; Lamberti G; Venkatraman D; Umeton R; Cherniack AD; Nishino M; Sholl LM; Shapiro GI; Awad MM; Cheng ML
    Clin Cancer Res; 2020 Aug; 26(15):4135-4142. PubMed ID: 32332016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational landscape of DNA damage response deficiency-related genes and its association with immune biomarkers in esophageal squamous cell carcinoma.
    Chen G; Zhu YJ; Chen J; Miao F; Wu N; Song Y; Mao BB; Wang SZ; Xu F; Chen ZM
    Neoplasma; 2022 Dec; 69(6):1314-1321. PubMed ID: 36264776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
    Weinberg BA; Xiu J; Hwang JJ; Shields AF; Salem ME; Marshall JL
    Oncologist; 2018 Oct; 23(10):1171-1177. PubMed ID: 29703766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach.
    Kim KB; Soroceanu L; de Semir D; Millis SZ; Ross J; Vosoughi E; Dar AA; Nosrati M; Desprez PY; Ice R; Chen M; Chetal K; Bhattacharjee A; Moretto J; Leong SP; Singer MI; Parrett BM; Minor DR; McAllister S; Miller JR; Salomonis N; Kashani-Sabet M
    J Invest Dermatol; 2021 Aug; 141(8):2028-2036.e2. PubMed ID: 33610559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort.
    Zhang W; Zhang L; Jiang H; Li Y; Wang S; Wang Q
    Aging (Albany NY); 2021 Nov; 13(21):24136-24154. PubMed ID: 34747718
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
    Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SMARCA4 Mutations in Carcinomas of the Esophagus, Esophagogastric Junction, and Stomach.
    Neil AJ; Zhao L; Isidro RA; Srivastava A; Cleary JM; Dong F
    Mod Pathol; 2023 Jun; 36(6):100183. PubMed ID: 37054973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
    Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
    Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mutational pattern of homologous recombination (HR)-associated genes and its relevance to the immunotherapeutic response in gastric cancer.
    Fan Y; Ying H; Wu X; Chen H; Hu Y; Zhang H; Wu L; Yang Y; Mao B; Zheng L
    Cancer Biol Med; 2020 Nov; 17(4):1002-1013. PubMed ID: 33299649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of DNA damage repair deficiency in 10,284 pan-cancer study.
    Xiao Y; Lu D; Lei M; Xie W; Chen Y; Zheng Y; Wang C; Zhao J; Zhu Z; Zhao X; Huang M; Lin Y; Li Z; Yang L
    Ann Transl Med; 2021 Nov; 9(22):1661. PubMed ID: 34988170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes identified using clinically actionable biomarker assays.
    Wang D; Elenbaas B; Murugesan K; Shah K; Montesion M; Gounaris I; Scheuenpflug J; Locatelli G; Feng Z
    NPJ Precis Oncol; 2023 Oct; 7(1):103. PubMed ID: 37821580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.
    van der Doelen MJ; Isaacsson Velho P; Slootbeek PHJ; Pamidimarri Naga S; Bormann M; van Helvert S; Kroeze LI; van Oort IM; Gerritsen WR; Antonarakis ES; Mehra N
    Eur J Cancer; 2020 Sep; 136():16-24. PubMed ID: 32634759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC.
    Park S; Lee H; Lee B; Lee SH; Sun JM; Park WY; Ahn JS; Ahn MJ; Park K
    J Thorac Oncol; 2019 Sep; 14(9):1640-1650. PubMed ID: 31125737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of tumor mutation burden and DNA damage repair in advanced stage non-small cell lung cancer patients.
    Zhang H; Deng YM; Chen ZC; Tang YC; Yang S; Zhang SD; Liang JM; Wang YG; Wu X; Zhang RW; Feng WN
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7664-7672. PubMed ID: 32744692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The enrichment of Fanconi anemia/homologous recombination pathway aberrations in ATM/ATR-mutated NSCLC was accompanied by unique molecular features and poor prognosis.
    Wei W; Shi F; Xu Y; Jiao Y; Zhang Y; Ou Q; Wu X; Yang L; Lai J
    J Transl Med; 2023 Dec; 21(1):874. PubMed ID: 38041093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.